Moderna to Present at the UBS 2022 Global Healthcare Conference

Rhea-AI Summary

Moderna (Nasdaq: MRNA) will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on May 24 at 9:15 a.m. ET. A live webcast will be available on the company's investor website, with a replay accessible for 30 days post-event. Moderna, known for its mRNA technology, has evolved from a research company to a leader in developing vaccines and therapeutics across various diseases, including COVID-19, reinforcing its position in the biopharmaceutical sector.

CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24^th at 9:15 a.m. ET.

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Investors: .
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc

View source version on accesswire.com:
https://www.accesswire.com/701870/Moderna-to-Present-at-the-UBS-2022-Global-Healthcare-Conference

FAQ

When will Moderna present at the UBS 2022 Global Healthcare Conference?

Moderna will present at the UBS 2022 Global Healthcare Conference on May 24, 2022, at 9:15 a.m. ET.

How can I watch the live presentation of Moderna's conference?

The live presentation can be viewed on Moderna's investor website under 'Events and Presentations'.

What is the significance of the UBS 2022 Global Healthcare Conference for Moderna?

The conference provides Moderna an opportunity to discuss its advancements in mRNA therapeutics and vaccines with investors.

What has Moderna achieved in the past decade?

In the last ten years, Moderna has developed a diverse portfolio of vaccines and therapeutics using mRNA technology and established significant manufacturing capabilities.

What technologies does Moderna focus on?

Moderna focuses on messenger RNA (mRNA) science, delivery technology, and manufacturing in the development of its therapeutics.